Neurontin (gabapentin) spends plenty of time in our patient’s medicine cabinets, but lately it has spent nearly as much time splashed across news sections of daily papers. Parke-Davis, the company that used to market Neurontin before it merged with Pfizer, has been accused of improperly promoting its use for a variety of off-label indications (1).

You can't view details of this content, please login or buy subscription here